{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:29:08Z","timestamp":1776259748410,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,4,4]],"date-time":"2009-04-04T00:00:00Z","timestamp":1238803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s11940-009-0019-3","type":"journal-article","created":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T09:56:04Z","timestamp":1238752564000},"page":"162-169","source":"Crossref","is-referenced-by-count":44,"title":["Drug-induced parkinsonism"],"prefix":"10.1007","volume":"11","author":[{"given":"Frandy","family":"Susatia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert H.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,4]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1192\/bjp.181.5.422","volume":"181","author":"J. Halliday","year":"2002","unstructured":"Halliday J, Farrington S, Macdonald S, et al.: Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002, 181:422\u2013427.","journal-title":"Br J Psychiatry"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.1961.03040120016004","volume":"175","author":"F.J. Ayd Jr","year":"1961","unstructured":"Ayd FJ Jr: A survey of drug-induced extrapyramidal reactions. JAMA 1961, 175:1054\u20131060.","journal-title":"JAMA"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0031-6997(25)06933-9","volume":"47","author":"M. Ebadi","year":"1995","unstructured":"Ebadi M, Srinivasan SK: Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 1995, 47:575\u2013604.","journal-title":"Pharmacol Rev"},{"key":"19_CR4","first-page":"737","volume":"112","author":"H. Steck","year":"1954","unstructured":"Steck H: [Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments.] [article in French]. Ann Med Psychol (Paris) 1954, 112:737\u2013744.","journal-title":"Ann Med Psychol (Paris)"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/089198879100400408","volume":"4","author":"L. Ganzini","year":"1991","unstructured":"Ganzini L, Heintz R, Hoffman WF, et al.: Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. J Geriatr Psychiatry Neurol 1991, 4:222\u2013225.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0920-9964(99)00133-4","volume":"42","author":"J. Modestin","year":"2000","unstructured":"Modestin J, Stephan PL, Erni T, Umari T: Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000, 42:223\u2013230.","journal-title":"Schizophr Res"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mds.20489","volume":"20","author":"P. Hobson","year":"2005","unstructured":"Hobson P, Gallacher J, Meara J: Cross-sectional survey of Parkinson\u2019s disease and parkinsonism in a rural area of the United Kingdom. Mov Disord 2005, 20:995\u2013998.","journal-title":"Mov Disord"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","volume":"62","author":"M.C. Rijk de","year":"1997","unstructured":"de Rijk MC, Tzourio C, Breteler MM, et al.: Prevalence of parkinsonism and Parkinson\u2019s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1997, 62:10\u201315.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.21854","volume":"23","author":"C.D. Esper","year":"2008","unstructured":"Esper CD, Factor SA: Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008, 23:401\u2013404.","journal-title":"Mov Disord"},{"key":"19_CR10","first-page":"397","volume":"16","author":"P.L. McGeer","year":"1977","unstructured":"McGeer PL, McGeer EG, Hattori T: Dopamine-acetylcholine-GABA neuronal linkages in the extrapyramidal and limbic systems. Adv Biochem Psychopharmacol 1977, 16:397\u2013402.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archpsyc.1983.01790090075012","volume":"40","author":"G.A. Keepers","year":"1983","unstructured":"Keepers GA, Clappison VJ, Casey DE: Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983, 40:1113\u20131117.","journal-title":"Arch Gen Psychiatry"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/ajp.143.2.232","volume":"143","author":"P. Moleman","year":"1986","unstructured":"Moleman P, Janzen G, von Bargen BA, et al.: Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. Am J Psychiatry 1986, 143:232\u2013234.","journal-title":"Am J Psychiatry"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1472-8206.1994.tb00808.x","volume":"8","author":"J.L. Montastruc","year":"1994","unstructured":"Montastruc JL, Llau ME, Rascol O, Senard JM: Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994, 8:293\u2013306.","journal-title":"Fundam Clin Pharmacol"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0091-3057(80)90182-3","volume":"12","author":"J.H. Gordon","year":"1980","unstructured":"Gordon JH, Gorski RA, Borison RL, Diamond BI: Postsynaptic efficacy of dopamine: possible suppression by estrogen. Pharmacol Biochem Behav 1980, 12:515\u2013518.","journal-title":"Pharmacol Biochem Behav"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/bmj.310.6977.447","volume":"310","author":"N. Quinn","year":"1995","unstructured":"Quinn N: Parkinsonism\u2014recognition and differential diagnosis. BMJ 1995, 310:447\u2013452.","journal-title":"BMJ"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","volume":"51","author":"R.J. Hardie","year":"1988","unstructured":"Hardie RJ, Lees AJ: Neuroleptic-induced Parkinson\u2019s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988, 51:850\u2013854.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archneur.1983.04050050093019","volume":"40","author":"C.G. Goetz","year":"1983","unstructured":"Goetz CG: Drug-induced Parkinsonism and idiopathic Parkinson\u2019s disease. Arch Neurol 1983, 40:325\u2013326.","journal-title":"Arch Neurol"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1212\/01.wnl.0000302255.49113.51","volume":"70","author":"M.V. Alvarez","year":"2008","unstructured":"Alvarez MV, Evidente VG: Understanding drug-induced parkinsonism: separating pearls from oy-sters. Neurology 2008, 70:e32\u2013e34.","journal-title":"Neurology"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s007020100006","volume":"108","author":"S. Hassin-Baer","year":"2001","unstructured":"Hassin-Baer S, Sirota P, Korczyn AD, et al.: Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 2001, 108:1299\u20131308.","journal-title":"J Neural Transm"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002590000460","volume":"28","author":"J. Booij","year":"2001","unstructured":"Booij J, Speelman JD, Horstink MW, Wolters EC: The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001, 28:266\u2013272.","journal-title":"Eur J Nucl Med"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2005.087262","volume":"56","author":"U. Merle","year":"2007","unstructured":"Merle U, Schaefer M, Ferenci P, Stremmel W: Clinical presentation, diagnosis and long-term outcome of Wilson\u2019s disease: a cohort study. Gut 2007, 56:115\u2013120.","journal-title":"Gut"},{"issue":"3Suppl","key":"19_CR22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1017\/S0317167100037823","volume":"14","author":"A.H. Rajput","year":"1987","unstructured":"Rajput AH, Uitti RJ, Stern W, et al.: Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson\u2019s disease. Can J Neurol Sci 1987, 14(3 Suppl):414\u2013418.","journal-title":"Can J Neurol Sci"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ageing\/18.3.208","volume":"18","author":"J.A. Wilson","year":"1989","unstructured":"Wilson JA, MacLennan WJ: Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989, 18:208\u2013210.","journal-title":"Age Ageing"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-002-1083-5","volume":"162","author":"S. Nyberg","year":"2002","unstructured":"Nyberg S, Olsson H, Nilsson U, Maehlum E, et al.: Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 2002, 162:37\u201341.","journal-title":"Psychopharmacology (Berl)"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02244811","volume":"106","author":"A.L. Nordstrom","year":"1992","unstructured":"Nordstrom AL, Farde L, Halldin C: Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992, 106:433\u2013438.","journal-title":"Psychopharmacology (Berl)"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","volume":"160","author":"J.A. Lieberman","year":"2003","unstructured":"Lieberman JA, Tollefson G, Tohen M, et al.: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003, 160:1396\u20131404.","journal-title":"Am J Psychiatry"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/00001756-200205070-00019","volume":"13","author":"S. Kapur","year":"2002","unstructured":"Kapur S, McClelland RA, VanderSpek SC, et al.: Increasing D2 affinity results in the loss of clozapine\u2019s atypical antipsychotic action. Neuroreport 2002, 13:831\u2013835.","journal-title":"Neuroreport"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","volume":"16","author":"D. Tarsy","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI: Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002, 16:23\u201345.","journal-title":"CNS Drugs"},{"issue":"Suppl9","key":"19_CR29","first-page":"25","volume":"65","author":"D.E. Casey","year":"2004","unstructured":"Casey DE: Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004, 65(Suppl 9):25\u201328.","journal-title":"J Clin Psychiatry"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4088\/JCP.v62n1001","volume":"62","author":"S.M. Stahl","year":"2001","unstructured":"Stahl SM: \u201cHit-and-run\u201d actions at dopamine receptors, part 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics. J Clin Psychiatry 2001, 62:747\u2013748.","journal-title":"J Clin Psychiatry"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","volume":"18","author":"J. Arnt","year":"1998","unstructured":"Arnt J, Skarsfeldt T: Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18:63\u2013101.","journal-title":"Neuropsychopharmacology"},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/archinte.165.16.1882","volume":"165","author":"P.A. Rochon","year":"2005","unstructured":"Rochon PA, Stukel TA, Sykora K, et al.: Atypical antipsychotics and parkinsonism. Arch Intern Med 2005, 165:1882\u20131888.","journal-title":"Arch Intern Med"},{"issue":"Suppl1","key":"19_CR33","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00002826-198300061-00004","volume":"6","author":"D. Tarsy","year":"1983","unstructured":"Tarsy D: Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983, 6(Suppl 1):S9\u2013S26.","journal-title":"Clin Neuropharmacol"},{"key":"19_CR34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9","volume":"14","author":"E.S. Molho","year":"1999","unstructured":"Molho ES, Factor SA: Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999, 14:1014\u20131016.","journal-title":"Mov Disord"},{"key":"19_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870120123","volume":"12","author":"K.A. Gwinn","year":"1997","unstructured":"Gwinn KA, Caviness JN: Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997, 12:119\u2013121.","journal-title":"Mov Disord"},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","volume":"27","author":"H.H. Fernandez","year":"2004","unstructured":"Fernandez HH, Trieschmann ME, Friedman JH: Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004, 27:4\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.10374","volume":"18","author":"H.H. Fernandez","year":"2003","unstructured":"Fernandez HH, Trieschmann ME, Burke MA, et al.: Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003, 18:510\u2013514.","journal-title":"Mov Disord"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/070674370404900119","volume":"49","author":"B.J. Connemann","year":"2004","unstructured":"Connemann BJ, Schonfeldt-Lecuona C: Ziprasidone in Parkinson\u2019s disease psychosis. Can J Psychiatry 2004, 49:73.","journal-title":"Can J Psychiatry"},{"issue":"7Suppl7","key":"19_CR39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852900026651","volume":"11","author":"D.E. Casey","year":"2006","unstructured":"Casey DE: Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006, 11(7 Suppl 7):25\u201331.","journal-title":"CNS Spectr"},{"key":"19_CR40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q","volume":"16","author":"S.A. Factor","year":"2001","unstructured":"Factor SA, Friedman JH, Lannon MC, et al.: Clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001, 16:135\u2013139.","journal-title":"Mov Disord"},{"key":"19_CR41","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511544163","volume-title":"A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs","author":"D.G.C. Owens","year":"1999","unstructured":"Owens DGC: A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge: Cambridge University Press; 1999."},{"key":"19_CR42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","volume":"87","author":"J. Gerlach","year":"1993","unstructured":"Gerlach J, Korsgaard S, Clemmesen P, et al.: The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993, 87:244\u2013252.","journal-title":"Acta Psychiatr Scand"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/mds.10255","volume":"17","author":"J.H. Kim","year":"2002","unstructured":"Kim JH, Jung HY, Kang UG, et al.: Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord 2002, 17:1354\u20131359.","journal-title":"Mov Disord"},{"key":"19_CR44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00004850-200301000-00007","volume":"18","author":"T. Inada","year":"2003","unstructured":"Inada T, Beasley CM Jr, Tanaka Y, Walker DJ: Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003, 18:39\u201348.","journal-title":"Int Clin Psychopharmacol"},{"key":"19_CR45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","volume":"76","author":"G. Chouinard","year":"2005","unstructured":"Chouinard G, Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005, 76:247\u2013265.","journal-title":"Schizophr Res"},{"key":"19_CR46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1461145701002589","volume":"4","author":"A.J. Loonen","year":"2001","unstructured":"Loonen AJ, Doorschot CH, van Hemert DA, et al.: The schedule for the assessment of drug-induced movement disorders (SADIMoD): inter-rater reliability and construct validity. Int J Neuropsychopharmacol 2001, 4:347\u2013360.","journal-title":"Int J Neuropsychopharmacol"},{"key":"19_CR47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"C.G. Goetz","year":"2007","unstructured":"Goetz CG, Fahn S, Martinez-Martin P, et al.: Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007, 22:41\u201347.","journal-title":"Mov Disord"},{"key":"19_CR48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/WNL.42.2.459","volume":"42","author":"A. Albanese","year":"1992","unstructured":"Albanese A, Colosimo C, Bentivoglio AR, Bergonzi P: Unsuspected, surreptitious drug-induced parkinsonism. Neurology 1992, 42:459.","journal-title":"Neurology"},{"key":"19_CR49","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ajhp\/54.21.2461","volume":"54","author":"L.C. Holloman","year":"1997","unstructured":"Holloman LC, Marder SR: Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 1997, 54:2461\u20132477.","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl21","key":"19_CR50","first-page":"15","volume":"62","author":"W.C. Wirshing","year":"2001","unstructured":"Wirshing WC: Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001, 62(Suppl 21):15\u201318.","journal-title":"J Clin Psychiatry"},{"key":"19_CR51","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1176\/ajp.133.8.940","volume":"133","author":"W.E. Fann","year":"1976","unstructured":"Fann WE, Lake CR: Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976, 133:940\u2013943.","journal-title":"Am J Psychiatry"},{"key":"19_CR52","first-page":"695","volume":"120","author":"T.S. Ing","year":"1979","unstructured":"Ing TS, Daugirdas JT, Soung LS, et al.: Toxic effects of amantadine in patients with renal failure. Can Med Assoc J 1979, 120:695\u2013698.","journal-title":"Can Med Assoc J"},{"key":"19_CR53","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0404.1994.tb01677.x","volume":"89","author":"E.N. Jansen","year":"1994","unstructured":"Jansen EN: Clozapine in the treatment of tremor in Parkinson\u2019s disease. Acta Neurol Scand 1994, 89:262\u2013265.","journal-title":"Acta Neurol Scand"},{"key":"19_CR54","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1212\/WNL.49.6.1587","volume":"49","author":"U. Bonuccelli","year":"1997","unstructured":"Bonuccelli U, Ceravolo R, Salvetti S, et al.: Clozapine in Parkinson\u2019s disease tremor. Effects of acute and chronic administration. Neurology 1997, 49:1587\u20131590.","journal-title":"Neurology"},{"key":"19_CR55","first-page":"155","volume":"9","author":"O. Hornykiewicz","year":"1975","unstructured":"Hornykiewicz O: Parkinsonism induced by dopaminergic antagonists. Adv Neurol 1975, 9:155\u2013164.","journal-title":"Adv Neurol"},{"key":"19_CR56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1353-8020(98)00032-7","volume":"4","author":"P.J. Garcia-Ruiz","year":"1998","unstructured":"Garcia-Ruiz PJ, Javier Jimenez-Jimenez F, Garcia de Yebenes J: Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson\u2019s disease. Parkinsonism Relat Disord 1998. 4:211\u2013214.","journal-title":"Parkinsonism Relat Disord"},{"key":"19_CR57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp.2003.020982","volume":"75","author":"G.F. Wooten","year":"2004","unstructured":"Wooten GF, Currie LJ, Bovbjerg VE, et al.: Are men at greater risk for Parkinson\u2019s disease than women? J Neurol Neurosurg Psychiatry 2004, 75:637\u2013639.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"19_CR58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/0897190007310514","volume":"20","author":"K.L. Claxton","year":"2007","unstructured":"Claxton KL, Chen JJ, Swope DM: Drug-induced movement disorders. J Pharm Pract 2007, 20:415\u2013429.","journal-title":"J Pharm Pract"},{"key":"19_CR59","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00127893-200211000-00006","volume":"8","author":"J.A. Gerpen Van","year":"2002","unstructured":"Van Gerpen JA: Drug-induced parkinsonism. Neurologist 2002, 8:363\u2013370.","journal-title":"Neurologist"},{"key":"19_CR60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14740338.4.1.91","volume":"4","author":"R.L. Rodnitzky","year":"2005","unstructured":"Rodnitzky RL: Drug-induced movement disorders in children and adolescents. Expert Opin Drug Saf 2005, 4:91\u2013102.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-009-0019-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-009-0019-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T21:02:40Z","timestamp":1739048560000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-009-0019-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,4]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11940-009-0019-3","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,4]]}}}